Biological E stand-alone is holding 200 million doses of Covid vaccine Corbevax, whereas Bharat Biotech is holding a stock of 50 million doses of Covaxin.
According to the news agency PTI, “The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received.”
According to the PTI report, Dr. Vikram Paradkar, senior vice president (manufacturing) of Biological E, said the company has produced a total dose of around 30 crores of Corbevax, meeting its vaccine manufacturing promise to the central government. In March 2022, Biological E supplies 10 crores of doses to the government.
“We have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly,” Dr. Vikram Paradkar informed PTI.
Biological E has collaborated with Texas Children’s Hospital Centre and Baylor College of Medicine (Baylor) in Houston, Texas, USA to develop the vaccines.
He further said “Biological E can begin with the additional vaccine supplies within eight weeks of future orders and can manufacture and supply approximately 10 crore doses of Corbevax monthly as per its qualified manufacturing capacity,” PTI reported.
“Bharat Biotech has more than 50 million doses of Covaxin readily available in vials, and over 200 million doses as a drug substance. Additional production capacity is also available to meet product demand,” the company authorities declared.
Read –DCGI grants Bharat Biotech permission to use the intranasal Covid-19 vaccine for emergency use.
